Semaglutide

Semaglutide is a high-efficacy prescription metabolic lever for people with obesity, type 2 diabetes, established cardiovascular disease, diabetic kidney disease, or MASH, but Semaglutide is a poor casual weight-loss shortcut. Wilding 2021 reported 14.9% mean weight loss at 68 weeks, Lincoff 2023 showed 20% lower 3-point MACE in high-risk adults without diabetes, and Perkovic 2024 added a kidney-outcome win in type 2 diabetes plus CKD. The catch is durability and supervision: appetite suppression can outpace protein intake, resistance training, hydration, eye monitoring, constipation prevention, and continuity planning. Semaglutide makes the most sense when cardiometabolic risk is high enough to justify chronic therapy, not when someone wants effortless leanness without rebuilding the rest of the system.

✅ Best for: Adults with obesity and type 2 diabetes, established cardiovascular disease plus overweight or obesity, diabetic CKD, obesity-related HFpEF symptoms, obesity with knee osteoarthritis, or noncirrhotic MASH with F2-F3 fibrosis who have tried serious lifestyle intervention and need a prescription-level metabolic lever. Semaglutide is strongest when used as medically supervised chronic therapy with protein targets, progressive resistance training, fiber, hydration, constipation prevention, eye monitoring in diabetes, and a realistic continuity plan. It is also reasonable when the near-term cardiometabolic risk is higher than the rare safety tail.

❌ Avoid if: You are metabolically healthy and chasing longevity microdosing, have personal or family history of MTC or MEN2, are pregnant or planning conception, have pancreatitis history, severe gastroparesis or GI motility disorder, active diabetic retinopathy risk without ophthalmology input, eating disorder history, recurrent dehydration, gallbladder disease, or upcoming anesthesia without clinician coordination. Avoid gray-market research peptides and poorly documented compounders. Also avoid if you are unwilling to resistance train, eat enough protein, and treat discontinuation planning as part of the protocol.